Filing Details
- Accession Number:
- 0001179110-15-011302
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-07-17 16:20:45
- Reporting Period:
- 2015-07-15
- Filing Date:
- 2015-07-17
- Accepted Time:
- 2015-07-17 16:20:45
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1280600 | Acceleron Pharma Inc | XLRN | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1586752 | D Steven Ertel | 128 Sidney Street Cambridge MA 02139 | Evp & Chief Operating Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2015-07-15 | 807 | $3.88 | 58,463 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2015-07-15 | 1,193 | $5.28 | 59,656 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2015-07-15 | 2,000 | $31.38 | 57,656 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Option to Purchase Common Stock | Disposition | 2015-07-15 | 807 | $0.00 | 807 | $3.88 |
| Common Stock | Option to Purchase Common Stock | Disposition | 2015-07-15 | 1,193 | $0.00 | 1,193 | $5.28 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 23,693 | 2020-12-02 | No | 4 | M | Direct | |
| 36,307 | 2021-12-16 | No | 4 | M | Direct |
Footnotes
- The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The options of registrant's common stock vest in equal quarterly installments over the first four years after the grant.
Billionaire Hedge Funds
